首页> 外国专利> NOVEL COUPLING COMPOUND, ITS PRODUCTION AND ITS USE AS MEDIUM IN DEVELOPMENT OF INTERFERON EFFECT

NOVEL COUPLING COMPOUND, ITS PRODUCTION AND ITS USE AS MEDIUM IN DEVELOPMENT OF INTERFERON EFFECT

机译:新型偶联化合物及其在干扰素作用研究中的产生及其在培养基中的用途

摘要

For the Contracting States : BE, CH, DE, FR, GB, IT, LI, LU, NL, SE 1. Coupling compounds represented by the formula (I) defined below : see diagramm : EP0203870,P77,F1 in which : - Y and T, identical or different, represent independently of one another O, S, Se or NH ; - Z and W, identical or different, represent independently of one another O, S, or NH ; - A represents adenine or one of its derivatives, particularly those of the formula : see diagramm : EP0203870,P77,F2 - SIGMA is a whole number equal to n-1, n being a whole number greater than or equal to 3 ; - m is a whole number greater than or equal to 0 and preferably greater than or equal to 2 ; - X is a whole number greater than or equal to 1, preferably comprised from 2 to 10 ; - Pr is a polypeptide chain comprising at least 5 amino acids, and the nitrogen atom belonging to the ring : see diagramm : EP0203870,P77,F3 belonging also to the end of a lateral sequence of the polypeptide Pr and/or belonging to a group see diagramm : EP0203870,P77,F4 coming from a COOH group modified by hydrazine. For the Contracting State : AT 1. Process for preparing coupling compounds of formula (I) : see diagramm : EP0203870,P85,F1 in which : - Y and T, identical or different, represent independently of one another O, S, Se or NH ; - Z and W, identical or different, represent independently of one another O, S, or NH ; - A represents adenine or one of its derivatives, particularly those of the formula : see diagramm : EP0203870,P85,F2 - SIGMA is a whole number equal to n-1, n being a whole number greater than or equal to 3 ; - m is a whole number greater than or equal to 0 and preferably greater than or equal to 2 ; - X is a whole number greater than or equal to 1, preferably comprised from 2 to 10 ; - Pr is a polypeptide chain comprising at least 5 amino acids, and the nitrogen atom belonging to the ring : see diagramm : EP0203870,P85,F3 belonging also to the end of a lateral sequence of the polypeptide Pr and/or belonging to a group see diagramm : EP0203870,P85,F4 coming from a COOH group modified by hydrazine characterized in that it comprises : - the oxidation of the starting compound of the following formula (Ibis) : see diagramm : EP0203870,P86,F5 in which Y, Z, T, W, A, m, SIGMA have the above mentioned meanings ; to introduce two aldehyde functions on to the carbons at the 2' and 3' positions of the last nucleoside unit and to obtain the compound of the following formula (Iter) : see diagramm : EP0203870,P86,F6 - the reductive alkylation of the compound (Iter) by a polypeptide Pr-NH2 whose chain comprises at particularly NH2 , this reaction taking place between the aldehyde functions of the compound (Iter) with the NH2 group of the polypeptide to obtain the compound of formula (I) : see diagramm : EP0203870,P86,F7 - the fractionation between the coupling compounds according to the invention and the uncoupled products particularly by molecular filtration.
机译:对于缔约国:BE,CH,DE,FR,GB,IT,LI,LU,NL,SE 1.由以下定义的式(I)表示的偶联化合物:参见示意图:EP0203870,P77,F1,其中:- Y和T相同或不同,彼此独立地表示O,S,Se或NH。 -Z和W相同或不同,彼此独立地表示O,S或NH; -A代表腺嘌呤或其衍生物之一,尤其是下式的那些:参见示意图:EP0203870,P77,F2-SIGMA是等于n-1的整数,n是大于或等于3的整数; -m是大于或等于0的整数,最好是大于或等于2的整数; -X是大于或等于1的整数,优选2至10; -Pr是包含至少5个氨基酸和属于环的氮原子的多肽链:参见示意图:EP0203870,P77,F3也属于多肽Pr的侧向序列的末端和/或属于一个基团参见图:来自由肼改性的COOH基团的EP0203870,P77,F4。对于缔约国:AT 1.制备式(I)偶联化合物的方法:参见示意图:EP0203870,P85,F1其中:-Y和T相同或不同,彼此独立地表示O,S,Se或NH; -Z和W相同或不同,彼此独立地表示O,S或NH; -A代表腺嘌呤或其衍生物之一,特别是下式的那些:参见示意图:EP0203870,P85,F2-SIGMA是等于n-1的整数,n是大于或等于3的整数; -m是大于或等于0的整数,最好是大于或等于2的整数; -X是大于或等于1的整数,优选2至10; -Pr是包含至少5个氨基酸和属于环的氮原子的多肽链:参见示意图:EP0203870,P85,F3也属于多肽Pr的侧向序列的末端和/或属于一个基团见图:来自被肼改性的COOH基团的EP0203870,P85,F4,其特征在于它包括:-下式(Ibis)的起始化合物的氧化:见图:EP0203870,P86,F5,其中Y,Z ,T,W,A,m,SIGMA具有上述含义;将两个醛官能团引入到最后一个核苷单元的2'和3'位置的碳上,并获得下式的化合物(Iter):参见示意图:EP0203870,P86,F6-该化合物的还原烷基化(Iter)通过多肽Pr-NH2(其链特别包含NH2)进行,该反应在化合物(Iter)的醛官能团与多肽的NH2基团之间发生,以获得式(I)的化合物: EP0203870,P86,F7-根据本发明的偶联化合物和未偶联产物之间的分馏,特别是通过分子过滤。

著录项

  • 公开/公告号JPS6216500A

    专利类型

  • 公开/公告日1987-01-24

    原文格式PDF

  • 申请/专利权人 CENTRE NATL RECH SCIENT CNRS;

    申请/专利号JP19860125562

  • 发明设计人 BERUNAARU RUBURUU;BERUNAARU BEYAARU;

    申请日1986-05-30

  • 分类号C07K16/00;A61K38/00;C07H21/00;C07H21/04;C07K1/113;C07K14/00;

  • 国家 JP

  • 入库时间 2022-08-22 07:27:08

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号